drugset / Trial / NCT06176911
The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia
Phase 2
Unknown
124 enrolled
Peking University People's Hospital
Beijing Friendship Hospital · collabBeijing Hospital · collabBeijing Luhe Hospital · collabBeijing Tsinghua Changgeng Hospital · collabChina-Japan Friendship Hospital · collabChinese PLA General Hospital · collabNavy General Hospital, Beijing · collabPeking University First Hospital · collabPeking University Third Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare the efficacy and safety of teriflunomide plus danazol versus danazol in patients with steroid-resistant/relapse ITP
Timeline
- Start
- 2023-12-05
- Primary completion
- 2024-12-30
- Completion
- 2025-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Danazol | Other / unclassified | 200 mg | — |
| Subject | Teriflunomide | Small molecule | 7 mg | Oral |